Quality-of-life priorities and travel burden vary substantially before cutaneous lymphoma radiotherapy

Among 82 cutaneous lymphoma patients, 38% prioritized quality of life, while those with Sézary syndrome traveled a median 201 km for RT.

KEY POINTS

  • This exploratory baseline analysis of the prospective S-MISR registry included 82 patients with primary cutaneous lymphoma referred for radiotherapy at a German specialist center between 2019 and 2024. Median age was 63 years, 59 patients (72%) had advanced-stage disease, and histologies comprised mycosis fungoides (n=56), Sézary syndrome (n=13) and other primary cutaneous lymphomas (n=13).
  • Before RT, patients completed the Quality–Quantity Questionnaire, Skindex-29 and EORTC QLQ-C30 to assess preferences for quality versus length of life and baseline symptom burden. 31 patients (38%) prioritized quality of life, 21 (25%) prioritized length of life, and 30 (37%) considered both equally important, demonstrating that treatment priorities could not be reliably inferred from diagnosis alone.
  • Travel requirements differed substantially by lymphoma subtype. Median travel distance was 201 km for Sézary syndrome, 114 km for mycosis fungoides and 65 km for other cutaneous lymphomas (overall p=0.009). The median distance across the entire cohort was 116 km, and 33/82 patients (40%) traveled more than 150 km to the treating center.
  • Specialized treatment accounted for much of this logistical burden. Total skin electron beam therapy (TSEBT) was planned for 69/82 patients (84%), including 55/56 with mycosis fungoides (98%) and 12/13 with Sézary syndrome (92%). In contrast, 11/13 patients (85%) with other cutaneous lymphoma subtypes were referred for local radiotherapy, indicating that travel distance was closely related to both disease type and access to specialized treatment.
  • Preference for quality of life was more frequent in patients older than 75 years (61% vs 33% in younger patients; p=0.05) and among those with ECOG performance status 2 versus 1 (54% vs 32%; p=0.03). Patients traveling more than 150 km also tended to prioritize quality of life more often (52% vs 29%; p=0.08); exploratory multivariable analysis identified associations with both age (p=0.019) and travel distance (p=0.029).
  • Baseline Skindex-29 global scores demonstrated greater health-related quality-of-life impairment in mycosis fungoides and Sézary syndrome than in other lymphoma subtypes. Median scores were 84, 95 and 52, respectively (p<0.001 for comparisons with non-MF/SS lymphomas), with worse symptoms, emotional burden and functioning in the two cutaneous T-cell lymphoma groups. Higher Skindex-29 scores indicate worse quality of life.
  • The analysis included no treatment-response, toxicity or post-RT quality-of-life outcomes, so it cannot establish whether particular radiation schedules improve patient priorities or reduce overall burden. Associations were exploratory without correction for multiple testing, and the referral-based single-center cohort, predominance of advanced T-cell lymphoma and nonvalidated three-category preference classification limit generalizability.

CLINICAL TAKEAWAY

Patients referred for cutaneous lymphoma radiotherapy differ considerably in how they value quality of life, survival and treatment-related logistical burden. Explicitly discussing these priorities and travel requirements may improve shared decision-making, particularly for TSEBT, but this exploratory baseline analysis does not establish which treatment schedule best addresses them.

SOURCE

Strahlentherapie und Onkologie

Browse more research Suggest a correction